Antimicrobials
Ciprofloxacin

Ciprofloxacin

High
N/A
IV-$4/d PO-$3/d

Spectrum of Activity

General Information

Cystic fibrosis, Pseudomonal infection

  • Renal and liver function
  • CBC
  • QTc in patients with increased risk
  • Tendinopathy and rupture have been reported.
  • Dizziness
  • Insomnia
  • Rash
  • Nausea, vomiting, abdominal pain
  • Tendinopathy and rupture
  • QTc prolongation have been reported
  • Strong CYP1A2 inhibitor and weak CYP3A4 inhibitor - Multiple interactions possible
  • QTc prolongation - Increased risk with other agents that prolong QTc
  • Increased risk of tendon rupture especially with concomitant use of corticosteroids.
  • Monitor INR with warfarin.
  • Avoid concurrent oral administration with calcium, antacids, iron. Administer ciprofloxacin 2 hours before or 4 hours after dose of calcium, antacids and iron.
  • Ciprofloxacin suspension should never be given through an enteral feeding tube. Ciprofloxacin immediate-release tablets can be given via tube, but should not be administered concurrently with enteral feedings. Discontinue feed for 1-2 hours prior to and after ciprofloxacin administration.

Not first-line therapy in children.

Antimicrobial class: Fluoroquinolone

Average serum half life: Pediatrics: 4-5 hours

Route of Elimination: 30% to 50% excreted as unchanged drug in urine via glomerular filtration and active tubular secretion; 20% to 40% excreted in feces primarily from biliary excretion; <1% excreted in bile as unchanged drug